About
Mr. Luci is a co-founder of Acurx Pharmaceuticals and has served as its President and Chief Executive Officer and as a director since February 2018. Previously he was President and Chief Executive Officer of Dipexium Pharmaceuticals (Nasdaq: DPRX), an antibiotic-focused pharmaceutical company, from February 2010 until its April 2017 sale to PLx Pharma Inc. (Nasdaq: PLXP) in a merger valued at $69.0 million. From 2009 to 2010 he served on the board of Abeona Therapeutics, where he chaired the Audit and Compensation Committees, and from 2007 to 2009 he was a director and President of MacroChem. Earlier he was Executive Vice President, Chief Financial Officer, General Counsel and Corporate Secretary of Bioenvision, Inc. He began his career as a certified public accountant with Ernst & Whinney (now Ernst & Young) and later practiced corporate law at Paul Hastings LLP. Mr. Luci holds a B.S. in Business Administration (Accounting) from Bucknell University and a J.D. from Albany Law School of Union University, and is a member of the New York State Bar Association.
Roles
External Roles
Fixed Compensation
FY 2024Performance Compensation
Data from FY 2024Cash incentive
Stock awards
Also at Acurx Pharmaceuticals, Inc.
See how Top Bucket AI works for your firm
Request DemoStay ahead of private markets
Research and market intelligence for private-markets professionals.
You're subscribed.
Thanks for signing up.